Literature DB >> 15300407

Type 1 and type 2 cytokine-producing CD4+ and CD8+ T cells in primary antiphospholipid syndrome.

Marina Karakantza1, Georgios L Theodorou, Nikolaos Meimaris, Athanasia Mouzaki, Ellul John, Andrew P Andonopoulos, Alice Maniatis.   

Abstract

Antiphospholipid syndrome (APS) is an autoimmune condition characterized by thrombosis and/or recurrent fetal loss as well as the presence of autoantibodies against epitopes present on phospholipid-binding proteins. The role of cellular immunity in the pathogenesis of the syndrome remains unclear. We studied the cellular phenotype and the production of type 1 [interferon (IFN)-gamma, interleukin (IL)-2] and type 2 (IL-4, IL-10) cytokines by CD4+ and CD8+ T-lymphocyte subsets in 13 patients with untreated primary APS (PAPS) and in 32 healthy controls. The production of cytokines was determined in T cells after a 5-h culture with or without mitogenic stimulation using a flow cytometric method of intracellular cytokine staining. In six of the patients these studies were repeated 6 months later. In PAPS patients we found a reduced percentage of circulating CD4+CD45RA+ and an increased percentage and absolute number of CD8+HLA-DR+ cells. A type 1 response was observed in the patients' unstimulated cells, indicated by an increase in IFN-gamma-producing CD8+, IL-2-producing CD4+ T cells, and a decrease in IL-4-producing CD4+ and CD8+ T cells. Similar results were obtained in the patients at follow-up. Taken together, these results suggest a chronic in vivo stimulation of CD4+ and CD8+ T cells in PAPS patients exhibiting a type 1 polarization. Changes of cellular immunity may contribute to the pathogenesis of the clinical manifestations of the syndrome and might be proven to be useful targets for therapeutic interventions in the future.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15300407     DOI: 10.1007/s00277-004-0910-7

Source DB:  PubMed          Journal:  Ann Hematol        ISSN: 0939-5555            Impact factor:   3.673


  9 in total

Review 1.  Systemic antiphospholipid syndrome and atherosclerosis.

Authors:  Luis J Jara; Gabriela Medina; Olga Vera-Lastra
Journal:  Clin Rev Allergy Immunol       Date:  2007-04       Impact factor: 8.667

2.  T cells demonstrate a Th1-biased response to native beta2-glycoprotein I in a murine model of anti-phospholipid antibody induction.

Authors:  Tanya Tolomeo; Angela Rico De Souza; Evan Roter; Mélanie Dieudé; Pascal Amireault; Rebecca Subang; Jerrold S Levine; Joyce Rauch
Journal:  Autoimmunity       Date:  2009-05       Impact factor: 2.815

3.  Significant changes in the levels of secreted cytokines in brains of experimental antiphospholipid syndrome mice.

Authors:  Assaf Menachem; Joab Chapman; Aviva Katzav
Journal:  Autoimmune Dis       Date:  2012-02-22

4.  CD8+DR+ T-Cells and C3 Complement Serum Concentration as Potential Biomarkers in Thrombotic Antiphospholipid Syndrome.

Authors:  Elizabeth Sarmiento; Jonathan Dale; Mauricio Arraya; Antonio Gallego; Nallibe Lanio; Joaquin Navarro; Javier Carbone
Journal:  Autoimmune Dis       Date:  2014-05-29

5.  Proteomic Analysis of Differentially Expressed Proteins in the Placenta of Anticardiolipin Antibody- (ACA-) Positive Pregnant Mice after Anzi Heji Treatment.

Authors:  Yazhen Xie; Qibin Lu
Journal:  Evid Based Complement Alternat Med       Date:  2020-12-14       Impact factor: 2.629

6.  Crassolide Suppresses Dendritic Cell Maturation and Attenuates Experimental Antiphospholipid Syndrome.

Authors:  Chi-Chien Lin; Yu-Kang Chang; Shih-Chao Lin; Jui-Hsin Su; Ya-Hsuan Chao; Kuo-Tung Tang
Journal:  Molecules       Date:  2021-04-24       Impact factor: 4.411

7.  Follicular helper and follicular regulatory T cell subset imbalance is associated with higher activated B cells and abnormal autoantibody production in primary anti-phospholipid syndrome patients.

Authors:  Yan Long; Wenyi Li; Jinghong Feng; Yinting Ma; Yuanyuan Sun; Lijuan Xu; Ying Song; Chen Liu
Journal:  Clin Exp Immunol       Date:  2021-08-22       Impact factor: 4.330

Review 8.  Revisiting the molecular mechanism of neurological manifestations in antiphospholipid syndrome: beyond vascular damage.

Authors:  M Carecchio; R Cantello; C Comi
Journal:  J Immunol Res       Date:  2014-03-13       Impact factor: 4.818

9.  Tolerogenic β2-glycoprotein I DNA vaccine and FK506 as an adjuvant attenuates experimental obstetric antiphospholipid syndrome.

Authors:  Ya-Hsuan Chao; Der-Yuan Chen; Joung-Liang Lan; Kuo-Tung Tang; Chi-Chien Lin
Journal:  PLoS One       Date:  2018-06-12       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.